Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Abbott has announced that Tandem Diabetes Care’s t:slim X2 insulin pump has become the first automated insulin delivery (AID) system to integrate with its newly available FreeStyle Libre 2 Plus sensor ...

DexCom ( DXCM -2.62%) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

The episode was not found or is unavailable. In this bonus episode Emma speaks to Dawn Adams, a midwife and menopause ...